Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + methocarbamol is an oral fixed-dose combination of two active pharmaceutical ingredients: ibuprofen and methocarbamol. **Ibuprofen** is a nonsteroidal anti-inflammatory drug (NSAID) that blocks cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis and thereby lowering pain, fever, and inflammation. **Methocarbamol** is a centrally acting muscle relaxant that acts mainly at the level of the central nervous system (spinal cord and brain), reducing muscle hyperactivity and spasms through CNS depression, though its precise mechanism remains incompletely defined. This combination provides symptomatic treatment of pain associated with muscle spasm, including back pain, muscle strains and sprains, and tense neck muscles. The combination is designed for short-term relief, aiming to combine analgesic, anti-inflammatory, and muscle relaxant effects[1][3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + methocarbamol.